-
1.发明申请COMPOSITION OF A FIRST NON-LABELED MONOCLONAL ANTIBODY BINDING TO A TUMOR ANTIGEN AND A NON-CROSS REACTIVE SECOND MONOCLONAL ANTIBODY LABELED WITH A NIR FLUORESCENCE LABEL 审中-公开第一个非标记的单克隆抗体与肿瘤抗原结合的组合物和标记有近红色荧光标记的非交叉反应性第二单克隆抗体
公开(公告)号：WO2008148546A2
公开(公告)日：2008-12-11
申请号：PCT/EP2008004456
申请日：2008-06-04
Applicant: HOFFMANN LA ROCHE , HASMANN MAX , LENZ HELMUT , SCHEUER WERNER
Inventor： HASMANN MAX , LENZ HELMUT , SCHEUER WERNER
CPC classification number: A61K49/0058 , A61K39/39558 , A61K49/0032
Abstract: This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patientwith such composition.
Abstract translation: 本发明涉及结合肿瘤抗原的非标记单克隆抗体的组合物和用NIR荧光标记标记的第二单克隆抗体，其结合相同的肿瘤抗原，其中第一抗体和第二抗体不表现出交叉反应性。 该组合物可用于治疗与这种肿瘤抗原的过表达相关的实体瘤患者。 本发明还涉及所述第一和第二抗体的共同给药，关于在用这种组合物治疗所述患者期间获得这种肿瘤的近红外荧光图像或患有这些肿瘤的患者的方法。
-
公开(公告)号：WO2006066912A3
公开(公告)日：2006-08-10
申请号：PCT/EP2005013849
申请日：2005-12-22
Applicant: HOFFMANN LA ROCHE , LENZ HELMUT , STUBENRAUCH KAY-GUNNAR
Inventor： LENZ HELMUT , STUBENRAUCH KAY-GUNNAR
IPC: G01N33/68
CPC classification number: G01N33/6854 , C07K16/4283
Abstract: The present invention relates to the field of therapeutic antibodies. It especially relates to the study of therapeutic antibodies in an experimental animal. The present invention discloses a method of detecting a therapeutic antibody in a sample obtained from an experimental animal comprising the steps of a) providing the sample to be analyzed, b) incubating said sample with an antibody binding to a therapeutic antibody and not binding to the immunoglobulin of said experimental animal, c) optionally incubating said sample with a reagent appropriate for the selective detection of total, active or antigen-bound therapeutic antibody, and d) correlating the complex formed in (b) or (c) to the concentration of said therapeutic antibody. A monoclonal antibody directed to a certain epitope that is present on all classes of human immunoglobulin of class G, but not on the immunoglobulin of any experimental animal except on the IgG of chimpanzees was used (MAB-M-R10Z8E9) .
Abstract translation: 本发明涉及治疗性抗体领域。 它特别涉及实验动物中治疗性抗体的研究。 本发明公开了一种检测从实验动物获得的样品中的治疗性抗体的方法，包括以下步骤：a）提供待分析的样品，b）将所述样品与结合治疗性抗体的抗体孵育， 所述实验动物的免疫球蛋白，c）任选地使用适于选择性检测总体，活性或抗原结合的治疗性抗体的试剂培养所述样品，以及d）使（b）或（c）中形成的复合物与 所述治疗性抗体。 （MAB-M-R10Z8E9）使用针对存在于G类人免疫球蛋白的所有类别但不在任何实验动物的免疫球蛋白上的特定表位的单克隆抗体，除了黑猩猩的IgG。
-
公开(公告)号：WO1994017072A1
公开(公告)日：1994-08-04
申请号：PCT/EP1994000195
申请日：1994-01-25
Applicant: BOEHRINGER MANNHEIM GMBH , HUBER, Erasmus , ZINK, Bruno , LENZ, Helmut , HOESS, Eva
Inventor： BOEHRINGER MANNHEIM GMBH
IPC: C07D495/04
CPC classification number: C07D495/04 , C12N9/00 , G01N33/532
Abstract: A compound has general formula (I), in which Bi is a residue obtained by splitting a carboxyl group from biotin or a biotin derivate; R and R represent independently from each other hydrogen or C1-C4-alkyl; n is an integer from 4 to 10; and X is an alkylene residue substituted by one or several O and/or S atoms, having a 5 to 20 atom long chain. Also disclosed is a conjugate of this compound with a substance having at least one primary and/or secondary amino group NHR .
-
4.发明申请DETECTION OF A TARGET ANTIGEN IRRESPECTIVE OF THE PRESENCE OR ABSENCE OF A CORRESPONDING THERAPEUTIC ANTIBODY 审中-公开检测相应抗精神病药物存在或不存在的目标抗原
公开(公告)号：WO2007003420A1
公开(公告)日：2007-01-11
申请号：PCT/EP2006/006524
申请日：2006-07-05
Applicant: F. HOFFMANN-LA ROCHE AG , LENZ, Helmut , SCHEUER, Werner , THIER, Martina
Inventor： LENZ, Helmut , SCHEUER, Werner , THIER, Martina
IPC: G01N33/53
CPC classification number: G01N33/53
Abstract: The present invention relates to the field of therapeutic antibodies. The invention especially relates to a method of detecting the target antigen of a therapeutic antibody in a sample comprising the steps of a) providing the sample to be analyzed, b) incubating said sample with said therapeutic antibody under conditions appropriate for binding of said therapeutic antibody to said target antigen, whereby a target antigen-therapeutic antibody-complex is formed, and c) detecting the complex formed in (b).
Abstract translation: 本发明涉及治疗性抗体领域。 本发明特别涉及一种检测样品中治疗性抗体的靶抗原的方法，包括以下步骤：a）提供待分析的样品，b）在适于所述治疗性抗体结合的条件下，将所述样品与所述治疗性抗体一起温育 由此形成靶抗原治疗型抗体复合体，c）检测（b）中形成的复合物。
-
公开(公告)号：WO2006066912A2
公开(公告)日：2006-06-29
申请号：PCT/EP2005/013849
申请日：2005-12-22
Applicant: F. HOFFMANN-LA ROCHE AG , LENZ, Helmut , STUBENRAUCH, Kay-Gunnar
Inventor： LENZ, Helmut , STUBENRAUCH, Kay-Gunnar
IPC: G01N33/68
CPC classification number: G01N33/6854 , C07K16/4283
Abstract: The present invention relates to the field of therapeutic antibodies. It especially relates to the study of therapeutic antibodies in an experimental animal. The present invention discloses a method of detecting a therapeutic antibody in a sample obtained from an experimental animal comprising the steps of a) providing the sample to be analyzed, b) incubating said sample with an antibody binding to a therapeutic antibody and not binding to the immunoglobulin of said experimental animal, c) optionally incubating said sample with a reagent appropriate for the selective detection of total, active or antigen-bound therapeutic antibody, and d) correlating the complex formed in (b) or (c) to the concentration of said therapeutic antibody.
Abstract translation: 本发明涉及治疗性抗体领域。 它特别涉及实验动物中治疗性抗体的研究。 本发明公开了一种检测从实验动物获得的样品中的治疗性抗体的方法，包括以下步骤：a）提供待分析的样品，b）将所述样品与结合治疗性抗体的抗体孵育， 所述实验动物的免疫球蛋白，c）任选地使用适于选择性检测总体，活性或抗原结合的治疗性抗体的试剂培养所述样品，以及d）使（b）或（c）中形成的复合物与 所述治疗性抗体。
-
Patent Agency Ranking
公开(公告)号：WO2008148546A3
公开(公告)日：2008-12-11
申请号：PCT/EP2008/004456
申请日：2008-06-04
Applicant: F.HOFFMANN-LA ROCHE AG , HASMANN, Max , LENZ, Helmut , SCHEUER, Werner
Inventor： HASMANN, Max , LENZ, Helmut , SCHEUER, Werner
Abstract: This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patientwith such composition.
-
公开(公告)号：WO2008119493A1
公开(公告)日：2008-10-09
申请号：PCT/EP2008/002395
申请日：2008-03-27
Applicant: F. HOFFMANN-LA ROCHE AG , LENZ, Helmut , SCHEUER, Werner
Inventor： LENZ, Helmut , SCHEUER, Werner
CPC classification number: A61K49/0058 , A61K49/0032
Abstract: This invention relates to a composition of labeled and non-labeled monoclonal antibodies directed to a human transmembrane protein for the simultaneous treatment and diagnosis of diseases which are associated with an overexpression of such a protein especially of cancer. The invention further relates to a method of first administering said composition, determine the change of labeled antibody concentration and afterwards administering the non-labeled monoclonal antibodies only such that the minimum required concentration of such non-labeled antibody for a favorable therapeutical effect is achieved and maintained in the treatment, while unfavorable side effects are minimized due to the lower systemic antibody concentration.
Abstract translation: 本发明涉及针对人跨膜蛋白的标记和非标记的单克隆抗体的组合物，用于同时治疗和诊断与这种特别是癌症的蛋白质的过度表达有关的疾病。 本发明还涉及首先施用所述组合物的方法，确定标记的抗体浓度的变化，然后仅施用非标记的单克隆抗体，使得达到有利治疗效果的这种非标记抗体的最低要求浓度， 维持治疗，而由于较低的全身抗体浓度，不利的副作用被最小化。
-
公开(公告)号：WO2005124382A1
公开(公告)日：2005-12-29
申请号：PCT/EP2005/052753
申请日：2005-06-14
Applicant: SIEMENS AKTIENGESELLSCHAFT , LENZ, Helmut
Inventor： LENZ, Helmut
IPC: G01R33/385
CPC classification number: G01R33/3852
Abstract: Bei einem Verfahren zum Steuern eines elektrischen Verstärkers (EV), bei dem ein eine Endstufe (ES) des Verstärkers (EV) ansteuerndes Reglersignal (RS) überwacht wird, wird das Reglersignal (RS) in Abhängigkeit eines Ausgangsignals (U out) der Endstufe (ES) eingestellt. Dabei wird das Reglersignal (RS) mit einem Referenzsignal (REFS) verglichen, wobei beim Durchschreiten eines Amplitudengrenzwertes (REF O, REF U) und eines Periodendauergrenzwertes (PGW) des Referenzsignals (REFS) vom jeweiligen Amplitudenwert (AW) bzw. Periodendauerwert (PW) des Reglersignals (RS) die Endstufe (ES) eingangsseitig sperrend angesteuert wird.
Abstract translation: 在用于控制电放大器（EV），一种方法，其中响应于所述输出级的输出信号（U出）的激活调节器信号（RS）的输出级中的放大器（EV）的（ES）被监控，调节器信号（RS）（ ES）设置。 在这里，调节器信号（RS）与比较的参考信号（REFS），并通过限幅值（REF O，U参考）的期间限制值从相应的幅度值（AW）和周期值的参考信号（REFS）的（PGW）经过时（PW）供给 调节信号（RS），输出级（ES）被控制在输入侧关闭。
-
公开(公告)号：WO2005050832A1
公开(公告)日：2005-06-02
申请号：PCT/EP2004/052889
申请日：2004-11-09
Applicant: SIEMENS AKTIENGESELLSCHAFT , LENZ, Helmut
Inventor： LENZ, Helmut
IPC: H03F3/217
CPC classification number: H03F3/2173 , H03F3/217 , H03F2200/351
Abstract: Die Erfindung betrifft einen elektrischen Verstärker mit einer Endstufe (6), die durch eine elektrische Energiequelle versorgbar ist, wobei die Endstufe (6) eingangsseitig mit einer Steuerungseinrichtung (4) verbunden ist, durch deren Steuersignal ein von einem Parameterwert der Energiequelle abhängiges Ausgangssignal der Endstufe (6) steuerbar ist. Gemäß der Erfindung ist eine Kompensationseinrichtung (9) vorgesehen, die mit der Energiequelle und der Steuerungseinrichtung (4) verbunden ist, und durch die das Steuersignal in Abhängigkeit von dem Parameterwert der Energiequelle veränderbar ist. Der Parameter kann z.B. die Netzspannung der Energiequelle sein. Die Erfindung betrifft weiter ein Verfahren zum Steuern eines elektrischen Verstärkers mit einer Endstufe (6), die durch eine elektrische Energiequelle versorgt wird, wobei ein Parameterwert der Energiequelle ermittelt, daraus ein Kompensationssignal abgeleitet und in Abhängigkeit davon ein Steuersignal für die Endstufe (6) gebildet wird. Der elektrische Verstärker und entsprechend das Verfahren können vorteilhaft als Gradientenverstärker für ein Magnetresonanzgerät eingesetzt werden.
Abstract translation: 本发明涉及具有可通过一个电功率源供应的输出级（6）的电放大器，其中在输入侧的控制装置（4）由所述输出级的所述能量源相关的输出信号的参数值的它的控制信号中的一个连接在所述输出级（6） （6）是可控制的。 根据提供了一种补偿装置（9）的发明中，其连接到所述电源和所述控制装置（4），和通过其根据能量源的参数值的控制信号是可变的。 该参数可以例如 是电源的电源电压。 本发明还涉及一种方法，用于控制电动放大器具有由电能源（6），其特征在于，确定所述能量源的一个参数值供电的输出级，从补偿信号导出的，并且形成用于输出级的控制信号（6），取决于 是。 电放大器，因此该方法可以被有利地用作用于磁共振装置的梯度放大器。
-
公开(公告)号：WO9913330A3
公开(公告)日：1999-06-17
申请号：PCT/EP9805521
申请日：1998-08-31
Applicant: ROCHE DIAGNOSTICS GMBH , HOESEL WOLFGANG , LENZ HELMUT , PETER JOCHEN
Inventor： HOESEL WOLFGANG , LENZ HELMUT , PETER JOCHEN
CPC classification number: C07K1/22 , B01D15/3804 , B01D15/422 , Y10S435/803 , Y10S435/81 , Y10S435/814 , Y10S435/815 , Y10S435/971 , Y10S435/975 , Y10S436/823 , Y10S436/824
Abstract: The invention relates to a method for purifying a target substance from a biological sample, involving immobilisation of the target substance on a solid phase through a high affinity binding pair, and follow-on elution through addition of a partner of the binding pair in a free form. The invention further relates to reagent kits for carrying out the inventive method.
Abstract translation: 本发明涉及一种方法，用于通过经由高亲和力通过加入游离形式的结合对的配偶体结合对和后续洗脱固定在固相上的目标物质纯化从生物样品中的目标物质。 此外试剂盒公开了用于实施该方法。
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.015 seconds)
